{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:12:23Z","timestamp":1767136343578,"version":"build-2238731810"},"reference-count":143,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,4,16]],"date-time":"2010-04-16T00:00:00Z","timestamp":1271376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal Cellular Physiology"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although the remarkable efficacy of biological therapy has resulted in significant success in inflammatory bowel disease (IBD) management, susceptibility to infections remains a concern. The biological agents include the tumor necrosis factor\u2010\u03b1 (TNF\u2010\u03b1) inhibitors, for instance infliximab, and other immunomodulating agents, such as natalizumab. Progressive multifocal leukoencephalopathy (PML), a rare but mostly fatal opportunistic brain infection caused by reactivation of the human polyomavirus JC virus (JCV), has been found in two patients with multiple sclerosis and one patient with Crohn's disease (CD), linked to treatment with natalizumab. After these cases of PML, the commercial and investigational use of natalizumab was suspended in February 2005 but was subsequently resumed for multiple sclerosis and for CD, only through a special restricted distribution program. This review, starting from an extensive literature search by the PubMed database, resumes the clinical aspects and pathophysiology of CD and focuses on the biologics in current use in CD (infliximab, adalimumab, and natalizumab), in order to provide a reference and gateway to prevention, recognition, and management of JCV, in the early years of biological agents therapy. It also proposed to provide an overview on the hypothetical mechanism of reactivation of JC virus related to the use of these drugs. J. Cell. Physiol. 224: 316\u2013326, 2010. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jcp.22146","type":"journal-article","created":{"date-parts":[[2010,4,16]],"date-time":"2010-04-16T12:26:49Z","timestamp":1271420809000},"page":"316-326","source":"Crossref","is-referenced-by-count":14,"title":["Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation"],"prefix":"10.1002","volume":"224","author":[{"given":"Anna","family":"Bellizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Barucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Fioriti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria T.","family":"Colosimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Mischitelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Anzivino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Chiarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Pietropaolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,5,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35393"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-37673-9_7"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2002.01067.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"A127","DOI":"10.1016\/S0016-5085(01)80623-5","article-title":"Azathioprine is more effective than oral 5\u2010ASA in the treatment of steroid\u2010dependent ulcerative colitis","volume":"120","author":"Ardizzone S","year":"2001","journal-title":"Gastroenterology"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21137"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/13550289609146907"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMe058122","article-title":"Progressive multifocal leukoencephalopathy and natalizumab\u2010unforeseen consequences","volume":"353","author":"Berger JR","year":"2005","journal-title":"N Engl J Med"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00381.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2007.11.013"},{"key":"e_1_2_10_11_1","first-page":"77","article-title":"Biologic targeting in the treatment of inflammatory bowel diseases","volume":"3","author":"Bosani M","year":"2009","journal-title":"Biologics"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520310002922"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)01034-5"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01343.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5258.60"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22657"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.59201000.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2007.02.018"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2004.02.014"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01639.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.111989"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/13550280601094563"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.23983"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006842-199805000-00007"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000194804.97164.86"},{"key":"e_1_2_10_27_1","first-page":"725","article-title":"IDEC\u2010131. IDEC\/Eisai","volume":"3","author":"Dumont FJ","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)01118-3"},{"key":"e_1_2_10_29_1","unstructured":"Elan and Biogen Idec Announce.2004.Elan and Biogen Idec announce ANTEGREN\u2010natalizumab\u2010phase III maintenance trial in Crohn's disease met its primary endpoint. Accessed on December 3 2008. Available from:http:\/\/www.elan.com."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2006.03.006"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)27571-1"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04040.x"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.26279"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)80125-7"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(08)80626-9"},{"key":"e_1_2_10_36_1","unstructured":"Food and Drug Administration.2006.Natalizumab (marketed as Tysabri) information. June 2006. Available at:http:\/\/www.fda.gov. Accessed July 17 2006."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2004.02.003"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.1.65"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI19836"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000194183.92671.b6"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020732"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1486"},{"key":"e_1_2_10_43_1","first-page":"373","article-title":"Therapeutic strategies for pediatric Crohn's disease","volume":"19","author":"Grand RJ","year":"1996","journal-title":"Clin Investig Med"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_10_45_1","first-page":"81","article-title":"The state of the art in the management of inflammatory bowel disease","volume":"3","author":"Hanauer SB","year":"2003","journal-title":"Rev Gastroenterol Disord"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.1.79-94.2002"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1373.2000.22335.x"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2004.00211.x"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00356.x"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.05.064"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/35079107"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1648"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043158"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)80123-3"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000257832.38943.2b"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705548"},{"key":"e_1_2_10_58_1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1128\/jcm.35.5.1255-1257.1997","article-title":"Persistent JC virus (JCV) infection is demonstrated by continuous shedding of the same JCV strains","volume":"35","author":"Kitamura T","year":"1997","journal-title":"J Clin Microbiol"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051782"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(93)90106-L"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/jemt.1090"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20933"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.2.253"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.133.5.558"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.116467"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i38.6102"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.4234"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051847"},{"key":"e_1_2_10_69_1","first-page":"66","article-title":"Emerging biologics therapies in inflamatory bowel disease","volume":"4","author":"Lim WC","year":"2004","journal-title":"Rev Gastroenterol Disord"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01809-06"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1086\/374739"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8553(01)00002-4"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22770"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.2000.00658.x"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2009.02.013"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.080708.082655"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.5.1.49"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033402"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-009-0138-3"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.1.143"},{"key":"e_1_2_10_82_1","first-page":"85","article-title":"JC virus and colorectal cancer: A possible trigger in the chromosomal instability pathway","volume":"21","author":"Niv Y","year":"2005","journal-title":"Curr Opin Gastroenterol"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-199708000-00003"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)91777-6"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.51.1.289"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01739.x"},{"key":"e_1_2_10_87_1","first-page":"CD000067","article-title":"Azathioprine for maintaining remission of Crohn's disease","volume":"2","author":"Pearson DC","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1339"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.11.6829"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.08.035"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.3.743"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-8-641"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2009.08.004"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng2032"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21688"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70252-5"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70332-X"},{"key":"e_1_2_10_99_1","first-page":"A61","article-title":"Preliminary results of a phase I\/II study of Huzaf, an anti\u2010IFN\u2010monoclonal antibody, in patients with moderate to severe active Crohn's disease","volume":"122","author":"Rutgeerts P","year":"2002","journal-title":"Gastroenterology"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01414.x"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.04.022"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1086\/344280"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2006.09.001"},{"key":"e_1_2_10_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.3780070504"},{"key":"e_1_2_10_105_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.025452"},{"key":"e_1_2_10_106_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.24042"},{"key":"e_1_2_10_107_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01661.x"},{"key":"e_1_2_10_108_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"e_1_2_10_109_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.33426"},{"key":"e_1_2_10_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08703.x"},{"key":"e_1_2_10_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.40462.x"},{"key":"e_1_2_10_112_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043335"},{"key":"e_1_2_10_113_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067594"},{"key":"e_1_2_10_114_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106781"},{"key":"e_1_2_10_115_1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00054725-199706000-00005","article-title":"Biologic therapy for inflammatory bowel disease","volume":"3","author":"Sands BE","year":"1997","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_2_10_116_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01179.x"},{"key":"e_1_2_10_117_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_10_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(03)00448-1"},{"key":"e_1_2_10_119_1","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1995.0029"},{"key":"e_1_2_10_120_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20196"},{"key":"e_1_2_10_121_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.24015"},{"key":"e_1_2_10_122_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062897"},{"key":"e_1_2_10_123_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5483.1352"},{"key":"e_1_2_10_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8553(05)70058-3"},{"key":"e_1_2_10_125_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200306000-00002"},{"key":"e_1_2_10_126_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.3.320"},{"key":"e_1_2_10_127_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.10.1383"},{"key":"e_1_2_10_128_1","doi-asserted-by":"publisher","DOI":"10.1385\/IR:27:2-3:529"},{"key":"e_1_2_10_129_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.10096"},{"key":"e_1_2_10_130_1","first-page":"A48","article-title":"Fontolizumab (Huzaftm), a humanized anti\u2010IFN\u2010gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease","volume":"53","author":"Van Assche G","year":"2004","journal-title":"Gut"},{"key":"e_1_2_10_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05907-5"},{"key":"e_1_2_10_132_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051586"},{"key":"e_1_2_10_133_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.089854"},{"key":"e_1_2_10_134_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00024.x"},{"key":"e_1_2_10_135_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.2000.00657.x"},{"key":"e_1_2_10_136_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.036160"},{"key":"e_1_2_10_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90277-5"},{"key":"e_1_2_10_138_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.145698"},{"key":"e_1_2_10_139_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.11.5189-5198.2004"},{"key":"e_1_2_10_140_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.25.022106.141557"},{"key":"e_1_2_10_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.05.024"},{"key":"e_1_2_10_142_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00542-09"},{"key":"e_1_2_10_143_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.1.30"},{"key":"e_1_2_10_144_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054693"}],"updated-by":[{"DOI":"10.1002\/jcp.24594","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T00:00:00Z","timestamp":1398211200000},"record-id":"10"}],"container-title":["Journal of Cellular Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcp.22146","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcp.22146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T17:20:53Z","timestamp":1696872053000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcp.22146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,22]]},"references-count":143,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1002\/jcp.22146"],"URL":"https:\/\/doi.org\/10.1002\/jcp.22146","archive":["Portico"],"relation":{},"ISSN":["0021-9541","1097-4652"],"issn-type":[{"value":"0021-9541","type":"print"},{"value":"1097-4652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,22]]}}}